Loading Cisplatin Onto 6-mercaptopurine Covalently Modified MSNS: a Nanomedicine Strategy to Improve the Outcome of Cisplatin Therapy

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2016 Dec 13

PMID 27942204

Citations 4

Authors

Xiaojie Lv

Ming Zhao

Yuiji Wang

Xi Hu

Jianhui Wu

Xueyun Jiang

Shan Li

Chunying Cui

Shiqi Peng

Affiliations

Soon will be listed here.

Abstract

In the treatment of cancer patients, cisplatin (CDDP) exhibits serious cardiac and renal toxicities, while classical combinations related to CDDP are unable to solve these problems and may result in worse prognosis. Alternately, this study covalently conjugated 6-mercaptopurine (6MP) onto the surface of mercapto-modified mesoporous silica nanoparticles (MSNS) to form MSNS-6MP and loaded CDDP into the holes on the surface of MSNS-6MP to form MSNS-6MP/CDDP, a tumor-targeting nano-releasing regime for CDDP and 6MP specifically. In the S180 mouse model, the anti-tumor activity and overall survival of MSNS-6MP/CDDP (50 mg·kg·day, corresponding to 1 mg·kg·day of 6MP and 5 mg·kg·day of CDDP) were significantly higher than those of CDDP alone (5 mg·kg·day) or CDDP (5 mg·kg·day) plus 6MP (1 mg·kg·day). The assays of serum alanine aminotransferase, aspartate aminotransferase and creatinine, as well as the images of myocardium and kidney histology, support that MSNS-6MP/CDDP is able to completely eliminate liver, kidney and heart toxicities induced by CDDP alone or CDDP plus 6MP.

Citing Articles

Redox/pH-responsive hollow manganese dioxide nanoparticles for thyroid cancer treatment.

Liu J, Guo C, Li C, Jia Q, Xie Z, Wang Z Front Chem. 2023; 11:1249472.

PMID: 37780983 PMC: 10540626. DOI: 10.3389/fchem.2023.1249472.

Nanoarchitectonics: Complexes and Conjugates of Platinum Drugs with Silicon Containing Nanocarriers. An Overview.

Piorecka K, Kurjata J, Stanczyk W Int J Mol Sci. 2021; 22(17).

PMID: 34502173 PMC: 8430569. DOI: 10.3390/ijms22179264.

A Study on Mesoporous Silica Loaded With Novel Photosensitizers HCE6 and Oxaliplatin for the Treatment of Cholangiocarcinoma.

Zhang P, Liu M, Fan F, Liu K Front Oncol. 2021; 11:665182.

PMID: 34268112 PMC: 8276239. DOI: 10.3389/fonc.2021.665182.

Toxicity evaluation of 6-mercaptopurine-Chitosan nanoparticles in rats.

Govindappa P, Joladarashi D, Hallur R, Sanganal J, Phani A Saudi Pharm J. 2020; 28(1):147-154.

PMID: 31933529 PMC: 6950973. DOI: 10.1016/j.jsps.2019.11.018.

References

Kounis N, Cervellin G, Lippi G . Cisplatin-induced bradycardia: Cardiac toxicity or cardiac hypersensitivity and Kounis syndrome?. Int J Cardiol. 2015; 202:817-8. DOI: 10.1016/j.ijcard.2015.10.027. View

Slowing I, Vivero-Escoto J, Wu C, Lin V . Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev. 2008; 60(11):1278-1288. DOI: 10.1016/j.addr.2008.03.012. View

Tiphaine A, Hjalgrim L, Nersting J, Breitkreutz J, Nelken B, Schrappe M . Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children. Eur J Pharm Sci. 2015; 83:1-7. DOI: 10.1016/j.ejps.2015.12.002. View

Ma T, Liu L, Yuan Z . Direct synthesis of ordered mesoporous carbons. Chem Soc Rev. 2012; 42(9):3977-4003. DOI: 10.1039/c2cs35301f. View

Carozzi V, Chiorazzi A, Canta A, Meregalli C, Oggioni N, Cavaletti G . Chemotherapy-induced peripheral neurotoxicity in immune-deficient mice: new useful ready-to-use animal models. Exp Neurol. 2014; 264:92-102. DOI: 10.1016/j.expneurol.2014.11.002. View

Bai M, Liu S . A simple and general method for preparing antibody-PEG-PLGA sub-micron particles using electrospray technique: an in vitro study of targeted delivery of cisplatin to ovarian cancer cells. Colloids Surf B Biointerfaces. 2014; 117:346-53. DOI: 10.1016/j.colsurfb.2014.02.051. View

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

Yang C, Wu C, Liaw C . Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy. Biomed J. 2016; 39(1):60-6. PMC: 6138775. DOI: 10.1016/j.bj.2015.08.006. View

Makrantonakis P, Ziotopoulos P, Agelidou A, Polyzos A, Ziras A, Chandrinos V . Vinorelbine and cisplatin combination in pretreated patients with advanced non-small cell lung cancer pretreated with a taxane-based regimen: a multicenter phase II study. Lung Cancer. 2006; 53(1):85-90. DOI: 10.1016/j.lungcan.2006.02.008. View

10.

Fennell D, Summers Y, Cadranel J, Benepal T, Christoph D, Lal R . Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat Rev. 2016; 44:42-50. DOI: 10.1016/j.ctrv.2016.01.003. View

11.

Ambrogio M, Thomas C, Zhao Y, Zink J, Stoddart J . Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc Chem Res. 2011; 44(10):903-13. PMC: 3196789. DOI: 10.1021/ar200018x. View

12.

Dasari S, Tchounwou P . Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014; 740:364-78. PMC: 4146684. DOI: 10.1016/j.ejphar.2014.07.025. View

13.

Reck M, Socinski M, Luft A, Szczesna A, Dediu M, Ramlau R . The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial. J Thorac Oncol. 2016; 11(6):808-18. DOI: 10.1016/j.jtho.2016.03.002. View

14.

Liu H, Zhang Y, Han Y, Zhao S, Wang L, Zhang Z . Characterization and cytotoxicity studies of DPPC:M(2+) novel delivery system for cisplatin thermosensitivity liposome with improving loading efficiency. Colloids Surf B Biointerfaces. 2015; 131:12-20. DOI: 10.1016/j.colsurfb.2015.04.029. View

15.

Tseng Y, Wang Y, Su C, Yang T, Chang T, Kau Y . Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: In vitro and in vivo studies. Colloids Surf B Biointerfaces. 2015; 134:254-61. DOI: 10.1016/j.colsurfb.2015.06.055. View

16.

Yao X, Panichpisal K, Kurtzman N, Nugent K . Cisplatin nephrotoxicity: a review. Am J Med Sci. 2007; 334(2):115-24. DOI: 10.1097/MAJ.0b013e31812dfe1e. View

17.

Watanabe K, Inai S, Jinnouchi K, Baba S, Yagi T . Expression of caspase-activated deoxyribonuclease (CAD) and caspase 3 (CPP32) in the cochlea of cisplatin (CDDP)-treated guinea pigs. Auris Nasus Larynx. 2003; 30(3):219-25. DOI: 10.1016/s0385-8146(03)00049-x. View

18.

Cortesi E, Ramponi S, Corona M, Moscetti L, Grifalchi F, Oliva A . Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15. Lung Cancer. 2001; 31(2-3):271-6. DOI: 10.1016/s0169-5002(00)00198-7. View

19.

Li J, Sun K, Ni L, Wang X, Wang D, Zhang J . Sodium selenosulfate at an innocuous dose markedly prevents cisplatin-induced gastrointestinal toxicity. Toxicol Appl Pharmacol. 2011; 258(3):376-83. DOI: 10.1016/j.taap.2011.11.020. View

20.

Niho S, Kenmotsu H, Sekine I, Ishii G, Ishikawa Y, Noguchi M . Combination chemotherapy with irinotecan and cisplatin for large-cell neuroendocrine carcinoma of the lung: a multicenter phase II study. J Thorac Oncol. 2013; 8(7):980-4. DOI: 10.1097/JTO.0b013e31828f6989. View